光韻達(300227.SZ):全資子公司與南京初芯、上海華力簽署戰略合作框架協議 擬在集成電路芯片領域合作
格隆匯 7 月 28日丨光韻達(300227.SZ)公佈,全資子公司深圳光韻達宏芯半導體科技有限公司(以下簡稱“光韻達宏芯”或“甲方1”)於近日與南京初芯集成電路有限公司(以下簡稱“南京初芯”或“甲方2”)、上海華力集成電路製造有限公司(以下簡稱“上海華力”或“乙方”)簽署了《戰略合作框架協議》,協議各方將發揮各自的優勢,密切合作,秉持“能力互補,互惠互利,平等自願,共贏發展”的原則,建立長期戰略合作關係,在eSRAM-SDM等相關集成電路芯片的研發和生產、銷售領域展開深度合作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.